Nevio Cimolai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8494423/publications.pdf

Version: 2024-02-01

129 papers	1,822 citations	304743 22 h-index	330143 37 g-index
131 all docs	131 docs citations	131 times ranked	1461 citing authors

#	Article	IF	Citations
1	Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. Journal of Pediatrics, 1990, 116, 589-592.	1.8	161
2	Definition and Application of a Histopathological Scoring Scheme for an Animal Model of Acute Mycoplasma pneumoniae Pulmonary Infection. Microbiology and Immunology, 1992, 36, 465-478.	1.4	119
3	Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics, 1992, 90, 616-21.	2.1	87
4	MRSA and the environment: implications for comprehensive control measures. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 481-493.	2.9	73
5	Zopiclone: is it a pharmacologic agent for abuse?. Canadian Family Physician, 2007, 53, 2124-9.	0.4	70
6	Mycoplasma pneumoniae as a Cofactor in Severe Respiratory Infections. Clinical Infectious Diseases, 1995, 21, 1182-1185.	5.8	61
7	Do the Â-Hemolytic Non-Group A Streptococci Cause Pharyngitis?. Clinical Infectious Diseases, 1988, 10, 587-601.	5.8	60
8	The potential and promise of mefenamic acid. Expert Review of Clinical Pharmacology, 2013, 6, 289-305.	3.1	58
9	A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clinical Nephrology, 1994, 42, 85-9.	0.7	52
10	Environmental and decontamination issues for human coronaviruses and their potential surrogates. Journal of Medical Virology, 2020, 92, 2498-2510.	5.0	48
11	Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma pneumoniae infection.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 638-639.	1.9	37
12	Beta-haemolytic non-group A streptococci and pharyngitis: A case-control study. European Journal of Pediatrics, 1991, 150, 776-779.	2.7	34
13	Hemolytic-Uremic Syndrome Associated with Acute <i>Campylobacter upsaliensis</i>Gastroenteritis. Nephron, 1996, 74, 489-489.	0.6	33
14	Yohimbine Use for Physical Enhancement and Its Potential Toxicity. Journal of Dietary Supplements, 2011, 8, 346-354.	2.6	33
15	Potentially repurposing adamantanes for COVIDâ€19. Journal of Medical Virology, 2020, 92, 531-532.	5.0	32
16	Methicillin-resistantStaphylococcus aureusin Canada: a historical perspective and lessons learned. Canadian Journal of Microbiology, 2010, 56, 89-120.	1.7	28
17	Features of enteric disease from human coronaviruses: Implications for COVIDâ€19. Journal of Medical Virology, 2020, 92, 1834-1844.	5.0	28
18	Implications of Yersinia enterocolitica biotyping.. Archives of Disease in Childhood, 1994, 70, 19-21.	1.9	27

#	Article	IF	Citations
19	Complicating Infections Associated with Common Endemic Human Respiratory Coronaviruses. Health Security, 2021, 19, 195-208.	1.8	27
20	The Complexity of Co-Infections in the Era of COVID-19. SN Comprehensive Clinical Medicine, 2021, 3, 1502-1514.	0.6	26
21	Immunological cross-reactivity of a Mycoplasma pneumoniae membrane-associated protein antigen with Mycoplasma genitalium and Acholeplasma laidlawii. Journal of Clinical Microbiology, 1987, 25, 2136-2139.	3.9	26
22	StaphylococcusaureusOutbreaks Among Newborns: New Frontiers in an Old Dilemma. American Journal of Perinatology, 2003, 20, 125-136.	1.4	23
23	Branhamella catarrhalis Bacteremia in Children. Acta Paediatrica, International Journal of Paediatrics, 1989, 78, 465-468.	1.5	22
24	IgM Anti-P1 Immunoblotting. Chest, 1992, 102, 477-481.	0.8	22
25	Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization. Vaccine, 1996, 14, 1479-1483.	3.8	22
26	The cranberry and the urinary tract. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 767-776.	2.9	22
27	The role of healthcare personnel in the maintenance and spread of methicillin-resistant Staphylococcus aureus. Journal of Infection and Public Health, 2008, 1, 78-100.	4.1	22
28	Do mycoplasmas cause human cancer?. Canadian Journal of Microbiology, 2001, 47, 691-7.	1.7	22
29	Rapid immunoblot method for diagnosis of acuteMycoplasma pneumoniae infection. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 223-226.	2.9	20
30	IgA Nephropathy Associated with Campylobacter jejuni Enteritis. Nephron, 1991, 58, 101-102.	1.8	19
31	Pastewella multocidachorioamnionitis from vaginal transmission. Acta Obstetricia Et Gynecologica Scandinavica, 1992, 71, 384-387.	2.8	17
32	Bases for the early immune response after rechallenge or component vaccination in an animal model of acute Mycoplasma pneumoniae pneumonitis. Vaccine, 1995, 13, 305-309.	3.8	17
33	Ocular Methicillin-resistant Staphylococcus Aureus Infections in a Newborn Intensive Care Cohort. American Journal of Ophthalmology, 2006, 142, 183-184.	3.3	17
34	Cyclobenzaprine: a new look at an old pharmacological agent. Expert Review of Clinical Pharmacology, 2009, 2, 255-263.	3.1	16
35	The epidemiology of beta-haemolytic non-Group A streptococci isolated from the throats of children over a one-year period. Epidemiology and Infection, 1990, 104, 119-126.	2.1	15
36	Corynebacterium pseudodiphtheriticum pneumonitis in a leukaemic child.. Thorax, 1992, 47, 838-839.	5.6	14

#	Article	IF	Citations
37	Diagnosis of whooping cough: A new era with rapid molecular diagnostics. Pediatric Emergency Care, 1996, 12, 91-93.	0.9	14
38	Candida dubliniensis Fungemia and Vascular Access Infection. Journal of Pediatric Hematology/Oncology, 2002, 24, 237-239.	0.6	14
39	More data are required for incubation period, infectivity, and quarantine duration for COVID-19. Travel Medicine and Infectious Disease, 2020, 37, 101713.	3.0	14
40	Mycoplasma pneumoniae associated arthropathy: confirmation of the association by determination of the antipolypeptide IgM response. Journal of Rheumatology, 1989, 16, 1150-2.	2.0	14
41	Culture-amplified immunological detection of Mycoplasma pneumoniae in clinical specimens. Diagnostic Microbiology and Infectious Disease, 1988, 9, 207-212.	1.8	13
42	Beta-D-glucuronidase activity assay for rapid differentiation of species within beta-haemolytic group C and G streptococci.. Journal of Clinical Pathology, 1991, 44, 824-825.	2.0	13
43	Selective media for isolation of Burkholderia (Pseudomonas) cepacia from the respiratory secretions of patients with cystic fibrosis.. Journal of Clinical Pathology, 1995, 48, 488-490.	2.0	13
44	Escherichia coli 0157: H7 infections associated with perforated appendicitis and chronic diarrhoea. European Journal of Pediatrics, 1990, 149, 259-260.	2.7	10
45	Acute Encephalomyelitis: Extending the Neurological Manifestations of Acute Rheumatic Fever?. Neuropediatrics, 1992, 23, 196-198.	0.6	10
46	Insertional Sequence Primers for Bordetella pertussis Diagnostic Polymerase Chain Reaction Differentiate Strains of Pseudomonas cepacia. Journal of Infectious Diseases, 1995, 172, 293-295.	4.0	10
47	A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19. SN Comprehensive Clinical Medicine, 2021, 3, 1272-1294.	0.6	10
48	Disinfection and decontamination in the context of SARSâ€CoVâ€2â€specific data. Journal of Medical Virology, 2022, 94, 4654-4668.	5.0	10
49	Mast Cell Biology and Linkages for Non-clonal Mast Cell Activation and Autoimmune/Inflammatory Syndrome Induced by Adjuvants. SN Comprehensive Clinical Medicine, 2020, 2, 2310-2323.	0.6	9
50	In pursuit of the right tail for the COVID-19 incubation period. Public Health, 2021, 194, 149-155.	2.9	9
51	Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19. SN Comprehensive Clinical Medicine, 2021, 3, 2093-2108.	0.6	9
52	Oxacillin susceptibility of coagulase-negative staphylococci: role for mecA genotyping and E-test susceptibility testing. International Journal of Antimicrobial Agents, 1997, 8, 121-125.	2.5	8
53	Bacterial genotype and neurological complications of Escherichia coli O157:H7-associated haemolytic uraemic syndrome. Acta Paediatrica, International Journal of Paediatrics, 2007, 87, 593-594.	1.5	8
54	Does oral vancomycin use necessitate therapeutic drug monitoring?. Infection, 2020, 48, 173-182.	4.7	8

#	Article	IF	Citations
55	A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. SN Comprehensive Clinical Medicine, 2020, 2, 2059-2066.	0.6	8
56	Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19. SN Comprehensive Clinical Medicine, 2020, 2, 2670-2683.	0.6	8
57	A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. Human and Experimental Toxicology, 2020, 39, 1279-1290.	2.2	8
58	Gender and the progression of Escherichia coli O157:H7 enteritis to haemolytic uraemic syndrome.. Archives of Disease in Childhood, 1991, 66, 171-172.	1.9	7
59	Not All Viral Culture Approaches Are Equal. Clinical Infectious Diseases, 2021, 73, e1787-e1788.	5.8	7
60	Defining protective epitopes for COVIDâ€19 vaccination models. Journal of Medical Virology, 2020, 92, 1772-1773.	5.0	7
61	Bacterial genotype and neurological complications of Escherichia coli O157:H7-associated haemolytic uraemic syndrome. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 593-594.	1.5	7
62	Do RNA vaccines obviate the need for genotoxicity studies?. Mutagenesis, 2020, 35, 509-510.	2.6	7
63	Impact of infection by verotoxigenic Escherichia coli O157:H7 on the use of surgical services in a children's hospital. Canadian Journal of Surgery, 1997, 40, 28-32.	1.2	7
64	Anti-smooth muscle antibody in clinical human and experimental animal Mycoplasma pneumoniae infection. Journal of Applied Microbiology, 1997, 82, 625-630.	3.1	6
65	Anti-Mycoplasma pneumoniae secretory antibody in human breast milk. Diagnostic Microbiology and Infectious Disease, 2002, 43, 247-250.	1.8	6
66	Chronic multifocal osteomyelitis: Is infectious causation a moot point?. Journal of Infection and Public Health, 2011, 4, 157-168.	4.1	6
67	Are Clostridium difficile toxins nephrotoxic?. Medical Hypotheses, 2019, 126, 4-8.	1.5	6
68	Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol. Clinical Medicine and Research, 2019, 17, 90-96.	0.8	6
69	Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences. International Journal of Antimicrobial Agents, 2021, 57, 106257.	2.5	6
70	Comparing histamine intolerance and non-clonal mast cell activation syndrome. Intestinal Research, 2020, 18, 134-135.	2.6	6
71	Enterobacterial intergenic consensus sequence polymerase chain reaction as a typing method for Burkholderia (Pseudomonas) cepacia. Clinical Microbiology and Infection, 1996, 2, 59-62.	6.0	5
72	Seroprevalence survey of borreliosis in children with chronic arthritis in British Columbia, Canada. Journal of Rheumatology, 1992, 19, 1620-4.	2.0	5

#	Article	IF	Citations
73	Invasive Streptococcus pyogenes infections in children. Canadian Journal of Public Health, 1992, 83, 230-3.	2.3	5
74	Mycoplasma pneumoniae Lacks Immunologically-Active Eukaryotic Actin-Like Antigens. Scandinavian Journal of Infectious Diseases, 1994, 26, 358-360.	1.5	4
75	Nosocomial transmission of penicillin-resistantStreptococcus pneumoniae. , 1999, 27, 432-434.		4
76	Preliminary concerns with vaccine vectors. Mutagenesis, 2020, 35, 359-360.	2.6	4
77	Reanalysis of quarantine for coronavirus disease 2019 with emerging data. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100291.	2.6	4
78	The semantics of airborne microbial spread and environmental relevance: Back to Anderson and Cox. Environmental Research, 2021, 193, 110448.	7.5	4
79	Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clinical Hematology International, 2021, 3, 47.	1.7	4
80	Correlation of erythromycin agar dilution susceptibility testing with disc diffusion susceptibility for Bordetella pertussis. International Journal of Antimicrobial Agents, 1997, 9, 113-116.	2.5	3
81	Severe Iron Deficiency Anemia and Gastrointestinal Dysfunction Associated with Ingestion of Pan Masala. Journal of Dietary Supplements, 2008, 5, 305-309.	2.6	3
82	Acetazolamide and Cardiac Failure. Clinical Drug Investigation, 2018, 38, 649-650.	2.2	3
83	Efficacy of povidoneâ€iodine to reduce viral load. Oral Diseases, 2020, 26, 1832-1832.	3.0	3
84	Cerebrovascular Disease Integration of Chronic Kidney Disease and Hypertension. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105519.	1.6	3
85	Mast cell biology in the context of dysautonomia and neuropathy. Clinical Immunology, 2020, 215, 108417.	3.2	3
86	Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences. International Journal of Antimicrobial Agents, 2021, 57, 106258.	2.5	3
87	Conflicting evidence on vertical transmission and maternal SARS-CoV-2 infection. Cmaj, 2020, 192, E1547-E1547.	2.0	3
88	Human Colorado tick fever in southern Alberta. Cmaj, 1988, 139, 45-6.	2.0	3
89	Mycoplasma pneumoniae Respiratory Infection. Pediatrics in Review, 1998, 19, 327-332.	0.4	3
90	Molecular diagnostics confirm the paucity of parapertussis activity. European Journal of Pediatrics, 2001, 160, 518-518.	2.7	2

#	Article	IF	Citations
91	Clinical validation for oxacillin susceptibility testing of coagulase negative staphylococci. Archives of Disease in Childhood, 2002, 86, 446-447.	1.9	2
92	Clioquinol for Otomycosis: A Lesser Understood Antimicrobial. Otology and Neurotology, 2020, 41, 141-142.	1.3	2
93	Perceptions of Silicone Structure and Function. Aesthetic Plastic Surgery, 2020, 44, 1914-1915.	0.9	2
94	Comment on â€œInsights into the pathogenesis of cystoid macular edema: leukostasis and related cytokinesâ€. International Journal of Ophthalmology, 2020, 13, 1343-1344.	1.1	2
95	Solidifying diagnostics in SARS-CoV-2 research. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100514.	2.6	2
96	The Neurological Spectrum for Acetazolamide Pharmacotherapy: from Basic Science to Clinical Applications. SN Comprehensive Clinical Medicine, 2021, 3, 2576-2592.	0.6	2
97	Bartonella henselae infection in British Columbia: evidence for an endemic disease among humans. Canadian Journal of Microbiology, 2000, 46, 908-12.	1.7	2
98	Transparency of disinfectant and hand sanitizer contents in the context of COVID-19. European Review for Medical and Pharmacological Sciences, 2021, 25, 2464-2467.	0.7	2
99	Immunophenotyping of SARS-CoV-2 and vaccine design. Vaccine, 2022, 40, 3985-3986.	3.8	2
100	Markers of Virulence Among Prospectively Acquired Putative EnteropathogenicEscherichia ColiSerogroups. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 267-274.	0.3	1
101	Lyme disease presenting as prolonged pyrexia of unknown origin. Clinical Microbiology and Infection, 1997, 3, 267-268.	6.0	1
102	Socks but no gloves. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 395-396.	2.9	1
103	Infections in the natural environment of British Columbia, Canada. Journal of Infection and Public Health, 2008, 1, 11-26.	4.1	1
104	The Canadian contribution to the science of verotoxigenicEscherichia coliand associated illnesses: the early years. Canadian Journal of Microbiology, 2013, 59, 709-715.	1.7	1
105	Animal visitation in acute care medical facilities. Cmaj, 2015, 187, 1236.2-1236.	2.0	1
106	Potential toxicity of topical ocular solutions. Cmaj, 2019, 191, E898-E898.	2.0	1
107	Delayed Antibiotic Prescribing in the Outpatient Setting. Journal of Pharmacy Practice, 2020, 33, 736-737.	1.0	1
108	Mast Cells in Periapical Pathology of Endodontics: Is There a Contribution to Systemic Disease?. International Journal of Oral-Medical Sciences, 2021, 20, 74-86.	0.1	1

#	Article	IF	Citations
109	Enzyme-Linked Immunoassay (Conventional Solid Phase). , 1999, , 69-76.		1
110	Co-detections versus coinfections in the context of SARS-CoV-2 diagnostics. Journal of Antimicrobial Chemotherapy, 2022, 77, 542-542.	3.0	1
111	Taking a long-term view of body sculpting. Cmaj, 2020, 192, E1730-E1730.	2.0	1
112	Utilization of herpes simplex PCR assays for cerebrospinal fluid in a pediatric health care setting. Canadian Journal of Microbiology, 2001, 47, 392-6.	1.7	1
113	Comment on: "COVID-19 and acute limb ischemia: a systematic review". Reconsidering human-associated coronavirus infections and idiopathic thrombosis. Journal of Cardiovascular Surgery, 2022, 63, 114.	0.6	1
114	Differentiation of species in human beta-haemolytic group G streptococci using immunoglobulin Fc fragment receptor.. Journal of Clinical Pathology, 1992, 45, 232-234.	2.0	0
115	Immunodominant antigens of Streptococcus equisimilis shared by other Â-haemolytic streptococci. Journal of Medical Microbiology, 1994, 40, 323-329.	1.8	0
116	Zopiclone overdose and flumazenil rescue. Cmaj, 2017, 189, E613-E613.	2.0	0
117	Fish processing and human infection. Cmaj, 2017, 189, E1400-E1400.	2.0	0
118	Night terrors associated with celiac disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 687-688.	1.6	0
119	Deciphering fatigue factor in chronic hepatitis B infection. Fatigue: Biomedicine, Health and Behavior, 2019, 7, 81-91.	1.9	0
120	Dilemmas in the recognition of SjÃ¶gren syndrome. Cmaj, 2019, 191, E1110-E1110.	2.0	0
121	Aminoglycosides and their potential as SARS-CoV-2 antivirals. Medical Hypotheses, 2021, 150, 110559.	1.5	0
122	Risk Factors for Angiotensionâ€Converting Enzyme Inhibitorâ€“Associated Cough. Journal of Clinical Pharmacology, 2021, 61, 1251-1252.	2.0	0
123	Mast cells, biomaterials, and posterior capsule opacification pathogenesis. European Journal of Ophthalmology, 2021, , 112067212110304.	1.3	0
124	Non-primate animal models for pertussis: back to the drawing board?. Applied Microbiology and Biotechnology, 2022, 106, 1383.	3.6	0
125	Markers of virulence among prospectively acquired putative enteropathogenic Escherichia coli serogroups. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 267-74.	0.3	0
126	Autoantibodies and COVID-19:  Rediscovering Nonspecific Polyclonal B-Cell Activation?. Journal of Infectious Diseases, 2022, , .	4.0	0

#	Article	IF	Citations
127	Cerebral Microvascular and Macrovascular Disease Risk Factors and COVID-19 Progression. Cerebrovascular Diseases, 2022, 51, 270-272.	1.7	0
128	MARKERS OF VIRULENCE AMONG PROSPECTIVELY ACQUIRED PUTATIVE ENTEROPATHOGENIC ESCHERICHIA COLI SEROGROUPS. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 267-274.	0.3	0
129	Epilepsy and clinically latent cerebrovascular disease. Epileptic Disorders, 2022, 24, 628-629.	1.3	0